Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus WESTADONE.
HYDROCODONE BITARTRATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Adults: 5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5-4 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class B), half-life may be prolonged to ~6 hours. In renal impairment (CrCl <30 mL/min), half-life may be extended by 30-50%.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal excretion of metabolites (primarily hydromorphone and norhydrocodone) accounts for approximately 99% of elimination, with less than 1% excreted unchanged. Biliary/fecal elimination is negligible.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist